Das benigne Prostatasyndrom

Machen Sie aus dem Träufeln wieder einen Fluss!


Ist Ihr Patient über 50 Jahre alt? Dann sollten Sie ihn nach Symptomen einer Prostatavergrößerung fragen. Wenn er über einen schwachen Harnstrahl, Harndrang und Nykturie berichtet, müssen Sie hellhörig werden. Informieren Sie sich hier über die notwendigen diagnostischen Schritte und die therapeutischen Möglichkeiten.

This is a preview of subscription content, access via your institution.


  1. 1.

    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol [Internet] 1984 Sep [cited 2014 Mar 26];132(3):474–479; available from: http://www.ncbi.nlm.nih.gov/pubmed/6206240

    CAS  PubMed  Google Scholar 

  2. 2.

    Handzel DM, Briesen S, Rausch S, Kälble T. Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complications. Dtsch Arztebl Int [Internet] 2012 May [cited 2012 Jul 18];109(21):379–384; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3371631&tool=pmcentrez&rendertype=abstract

    PubMed Central  PubMed  Google Scholar 

  3. 3.

    Steers WD. 5alpha-reductase activity in the prostate. Urology [Internet] 2001 Dec [cited 2014 Mar 26];58(6 Suppl 1):17–24; discussion 24; available from: http://www.ncbi.nlm.nih.gov/pubmed/11750244

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Gravas S, Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Uroweb 2014; available at: http://www.uroweb.org/guidelines/online-guidelines/?no_cache=1, accessed May 20, 2014

    Google Scholar 

  5. 5.

    Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med [Internet] 1995 Jan 12 [cited 2014 Mar 26];332(2):75–79; available from: http://www.ncbi.nlm.nih.gov/pubmed/7527493

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Netto NR, de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology [Internet] 1999 Feb [cited 2014 Mar 26];53(2):314–316; available from: http://www.ncbi.nlm.nih.gov/pubmed/9933046

    PubMed  Article  Google Scholar 

  7. 7.

    Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology [Internet] 2008 Jan [cited 2014 Mar 26];82(4):270–275; available from: http://www.ncbi.nlm.nih.gov/pubmed/18849646

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis [Internet] 2004 Jan [cited 2014 Mar 26];7(3):195–200; available from: http://www.ncbi.nlm.nih.gov/pubmed/15289814

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2000 Jan [cited 2014 Mar 26];(2):CD001043; available from: http://www.ncbi.nlm.nih.gov/pubmed/10796740

    PubMed  Google Scholar 

  10. 10.

    Schulz V, Hänsel R. Rationale Phytotherapie [Internet] Berlin, Heidelberg: Springer Berlin Heidelberg; 2004 [cited 2014 Mar 26]; available from: http://www.springerlink.com/index/10.1007/978-3-642-18842-8

    Google Scholar 

  11. 11.

    Wilt T, Ishani A, MacDonald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(1): CD001044. http://www.ncbi.nlm.nih.gov/pubmed/11869585

    PubMed  Google Scholar 

  12. 12.

    Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2000 Jan [cited 2014 Mar 26];(2):CD001042; available from: http://www.ncbi.nlm.nih.gov/pubmed/10796739

    PubMed  Google Scholar 

  13. 13.

    Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2012 Jan [cited 2014 Mar 26];12:CD001423; available from: http://www.ncbi.nlm.nih.gov/pubmed/23235581

    PubMed  Google Scholar 

  14. 14.

    Kortmann BBM, Floratos DL, Kiemeney LALM, Wijkstra H, de la Rosette JJMCH. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology [Internet] 2003 Jul [cited 2014 Mar 26];62(1):1–9; available from: http://www.ncbi.nlm.nih.gov/pubmed/12837408

    PubMed  Article  Google Scholar 

  15. 15.

    Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate [Internet] 1997 Sep 15 [cited 2014 Mar 26];33(1):55–59; available from: http://www.ncbi.nlm.nih.gov/pubmed/9294627

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract [Internet] 2008 Oct [cited 2014 Mar 26];62(10):1547–1559; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2658011&tool=pmcentrez&rendertype=abstract

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  17. 17.

    Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology [Internet] 2004 Dec [cited 2014 Mar 26];64(6):1081–1088; available from: http://www.ncbi.nlm.nih.gov/pubmed/15596173

    PubMed  Article  Google Scholar 

  18. 18.

    Handzel DM, Rausch S, Kälble T, Briesen S. [Managing complications in intraoperative floppy iris syndrome.] Ophthalmologe [Internet] 2013 Jan 23 [cited 2013 Jan 27]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23338529

    Google Scholar 

  19. 19.

    Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol [Internet] 2004 Oct [cited 2014 Mar 26];172(4 Pt 1):1399–1403; available from: http://www.ncbi.nlm.nih.gov/pubmed/15371854

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther [Internet] 2007 Jan [cited 2014 Mar 26];29(1):17–25; available from: http://www.ncbi.nlm.nih.gov/pubmed/17379044

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology [Internet] 1996 Sep [cited 2014 Mar 26];48(3):398–405; available from: http://www.ncbi.nlm.nih.gov/pubmed/8804493

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int [Internet] 2005 Sep [cited 2014 Mar 26];96(4):572–577; available from: http://www.ncbi.nlm.nih.gov/pubmed/16104912

    PubMed  Article  Google Scholar 

  23. 23.

    Gittelman M, Ramsdell J, Young J, McNicholas T. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol [Internet] 2006 Sep [cited 2014 Mar 26];176(3):1045–1050; discussion 1050; available from: http://www.ncbi.nlm.nih.gov/pubmed/16890688

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med [Internet] 1996 Aug 22 [cited 2014 Mar 26];335(8):533–539; available from: http://www.ncbi.nlm.nih.gov/pubmed/8684407

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology [Internet] 2003 Jan [cited 2014 Mar 26];61(1):119–126; available from: http://www.ncbi.nlm.nih.gov/pubmed/12559281

    PubMed  Article  Google Scholar 

  26. 26.

    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT stu. Eur Urol [Internet] 2009 Feb [cited 2014 Mar 26];55(2):461–471; available from: http://www.ncbi.nlm.nih.gov/pubmed/19013011

    PubMed  Article  Google Scholar 

  27. 27.

    Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol [Internet] 2008 Dec [cited 2014 Mar 26];26(6):603-609; available from: http://www.ncbi.nlm.nih.gov/pubmed/18607596

    Google Scholar 

  28. 28.

    Uckert S, Oelke M, Stief CG, Andersson K-E, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol [Internet] 2006 Apr [cited 2014 Mar 26];49(4):740–745; available from: http://www.ncbi.nlm.nih.gov/pubmed/16460876

    PubMed  Article  Google Scholar 

  29. 29.

    Uckert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol [Internet] 2001 Dec [cited 2014 Mar 26];166(6):2484–2490; available from: http://www.ncbi.nlm.nih.gov/pubmed/11696815

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol [Internet] 2008 Feb [cited 2014 Mar 27];179(2):616–621; discussion 621; available from: http://www.ncbi.nlm.nih.gov/pubmed/18082216

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive detrusor. BJU Int 2004 Oct;94(6):817–820; http://www.ncbi.nlm.nih.gov/pubmed/15476515

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009 Dec;182(6):2825–2833; http://www.ncbi.nlm.nih.gov/pubmed/19837435

    PubMed  Article  Google Scholar 

  33. 33.

    Athanasopoulols A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized,controlled study. J Urol 2003 Jun;169(6):2253–2256

    Article  Google Scholar 

  34. 34.

    Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol 2009;56:534–543

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Arenas da Silva LF, Schönthaler M, Cruz F, Gratzke C, Zumbe J, Stenzl A, Amend B, Sievert KD. [New treatment strategies for male lower urinary tract symptoms] Urologe A 2012 Dec;51(12):1697–1702. doi: 10.1007/s00120-012-3032-1. German. PMID: 23139025 [PubMed - indexed for MEDLINE]

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 2013 Aug;64(2): 292–299; doi: 10.1016/j.eururo.2013.01.008. Epub 2013 Jan 19. PMID: 23357348 [PubMed - indexed for MEDLINE]

    PubMed  Article  Google Scholar 

  37. 37.

    Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH. Multicentre prospective crossover study of the xxx201A;prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014 Apr;113(4):615–622; doi: 10.1111/bju.12540. PubMed PMID: 24765680

    PubMed  Article  Google Scholar 

  38. 38.

    Marchal C, Perez JE, Herrera B et al. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012 Jan; 31(1):86–92

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006 Mar;175(3 Pt 1):1158–1163

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Brisinda G, Cadeddu F, Vanella S et al. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009 Jan;73(1):90–94

    PubMed  Article  Google Scholar 

  41. 41.

    Varkarakis J, Bartsch G, Horninger W. Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate [Internet] 2004 Feb 15 [cited 2014 Mar 27];58(3):248–251; available from: http://www.ncbi.nlm.nih.gov/pubmed/14743463

    PubMed  Article  Google Scholar 

  42. 42.

    Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol [Internet] 2001 May [cited 2014 Mar 27];165(5):1526–1532; available from: http://www.ncbi.nlm.nih.gov/pubmed/11342911

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med [Internet] 1989 Apr 27 [cited 2014 Mar 27];320(17): 1120–1124; available from: http://www.ncbi.nlm.nih.gov/pubmed/2469015

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol [Internet] 2006 Nov [cited 2014 Mar 27];50(5):969–979; discussion 980; available from: http://www.ncbi.nlm.nih.gov/pubmed/16469429

    PubMed  Article  Google Scholar 

  45. 45.

    Rassweiler J, Schulze M, Stock C, Teber D, De La Rosette J. Bipolar transurethral resection of the prostate - technical modifications and early clinical experience. Minim Invasive Ther Allied Technol [Internet] 2007 Jan [cited 2014 Mar 27];16(1):11-21; available from: http://www.ncbi.nlm.nih.gov/pubmed/17365673

    Google Scholar 

  46. 46.

    Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Thomas JA. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial - the GOLIATH study. Eur Urol 2014 May;65(5):931–942; doi: 10.1016/j.eururo.2013.10.040. Epub 2013 Nov 11. PubMed PMID: 24331152.

    PubMed  Article  Google Scholar 

  47. 47.

    Le Duc A, Gilling PJ. Holmium laser resection of the prostate. Eur Urol [Internet] 1999 Feb [cited 2014 Mar 27];35(2):155–160; available from: http://www.ncbi.nlm.nih.gov/pubmed/9933809

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg [Internet] 2007 Oct [cited 2014 Mar 27];94(10):1201–1208; available from: http://www.ncbi.nlm.nih.gov/pubmed/17729384

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ [Internet] 2008 Jan [cited 2014 Mar 27];337:a449; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2443595&tool=pmcentrez&rendertype=abstract

    PubMed  Article  Google Scholar 

  50. 50.

    Kabalin JN, Mackey MJ, Cresswell MD, Fraundorfer MR, Gilling PJ. Holmium: YAG laser resection of prostate (HoLRP) for patients in urinary retention. J Endourol [Internet] 1997 Aug [cited 2014 Mar 27];11(4):291–293; available from: http://www.ncbi.nlm.nih.gov/pubmed/9376851

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Rieken M, Bachmann A, Gratzke C. Laservaporization of the prostate: current status of the greenlight and diode laser. Urologe A [Internet] 2013 Mar [cited 2014 Mar 30];52(3):339–344; available from: http://www.ncbi.nlm.nih.gov/pubmed/23429879

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol [Internet] 2011 Sep [cited 2014 Mar 30];186(3):977–981; available from: http://www.ncbi.nlm.nih.gov/pubmed/21791350

    PubMed  Article  Google Scholar 

  53. 53.

    Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70 g: 24-month follow-up. Eur Urol [Internet] 2006 Sep [cited 2014 Mar 27];50(3):563–568; available from: http://www.ncbi.nlm.nih.gov/pubmed/16713070

    PubMed  Article  Google Scholar 

  54. 54.

    Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol [Internet] 2008 Oct [cited 2014 Mar 27];22(10):2333–2340; available from: http://www.ncbi.nlm.nih.gov/pubmed/18837655

    PubMed  Article  Google Scholar 

  55. 55.

    Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol [Internet] 2008 Jan [cited 2014 Mar 27];53(1):160–166; available from: http://www.ncbi.nlm.nih.gov/pubmed/17869409

    PubMed  Article  Google Scholar 

  56. 56.

    Gratzke C, Schlenker B, Seitz M, Karl A, Hermanek P, Lack N, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol [Internet] 2007 Apr [cited 2014 Mar 27];177(4):1419–1422; available from: http://www.ncbi.nlm.nih.gov/pubmed/17382744

    PubMed  Article  Google Scholar 

  57. 57.

    Gravas S (chair), Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benigin prostatic obstruction (BPO), http://www.uroweb.org/guidelines/online-guidelines/, ISBN 978-90-79754-65-6

Download references

Author information



Corresponding author

Correspondence to Prof. Dr. med. Karl-Dietrich Sievert.

Additional information


Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Herr Dr. Rausch legt folgende potenzielle Interessenkonflikte offen: keine. Herr Prof. Sievert: Neotract (Urolift®) Investigator BPH6-Study.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rausch, S., Sievert, KD. Machen Sie aus dem Träufeln wieder einen Fluss!. MMW - Fortschritte der Medizin 156, 78–85 (2014). https://doi.org/10.1007/s15006-014-3297-y

Download citation

Keywords - Lower urinary tract symptoms associated with benign prostatic enlargement

  • Bladder outlet obstruction
  • prostate
  • TURP
  • TVP
  • LUTS
  • PUL